In their quest to understand how cancers take root, grow and spread, scientists have for the past half-century explored the ...

Researchers in Purdue University's College of Pharmacy have developed and validated a new series of small-molecule inhibitors ...

InxMed Co., Ltd ('InxMed'), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting ...

SSRIs enhance CD8 T cell antitumor activity by inhibiting SERT, an immune checkpoint in tumors, suggesting potential repurposing for cancer immunotherapy. High intratumoral SERT levels correlate with ...

Preclinical manuscript that characterizes the mechanism of action, broad antitumor efficacy, and immune-activating properties ...

A HER3-DXd and olaparib combination enhanced DNA damage, apoptosis, and antitumor immune activity in preclinical NSCLC models.

First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), providing a safe and effective oral targeted ...

Mayhem under the microscope: T cell cytotoxicity and serial killers captured in situ. Association of lymphopenia rescue and CA19-9 levels with overall survival following IL-15 superagonist N-803 and ...

Zhong-Yin Zhang leads a team that has developed and validated a novel series of small-molecule inhibitors that promote ...